Between 2010 and 2020, drug companies across the world spent more than £1.2trillion trying to find new ways to cure diseases. Much of that money was devoted to seeking treatments
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost
Leading law firm, BDB Pitmans, has advised long-term clients Arden Partners plc and finnCap Ltd on Poolbeg Pharma plc’s IPO for London’s AIM market. The placing completed on 19 July
It has been a steady few weeks for Poolbeg Pharma, after a successful trading launch on the Alternative Investment Market, London Stock Exchange’s space for small- and medium-size growth companies.
A new UK company, Poolbeg Pharma, has been set up to develop new anti-infectives in an efficient manner, and already has a repositioned MAP kinase inhibitor for the treatment of
Infectious disease specialist Poolbeg Pharma is planning to list on New York’s Nasdaq in the coming months, according to its chairman Cathal Friel. The company was last week spun out
Poolbeg Pharma plc (LON:POLB), a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has announced that admission of its entire issued share capital to trading on the
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
